Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) and and the Coalition for Epidemic Preparedness Innovations (CEPI) announced on Monday that CEPI has awarded Valneva an additional USD41.3m to expand access to IXCHIQ, the world's first chikungunya vaccine.
This funding will support broader access to the vaccine in low- and middle-income countries, as well as post-marketing trials and potential label extensions in children, adolescents and pregnant women.
CEPI will provide the funds to Valneva over the next five years, with support from the European Union's Horizon Europe programme.
The project will help generate additional data to potentially support extended IXCHIQ labels in chikungunya-endemic countries and vulnerable populations at risk of being infected with the disease.
Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint pain, muscle pain, headache, nausea, fatigue and rash.
myTomorrows names new director
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
Latigo Biotherapeutics names new chief executive officer
Valneva receives CEPI funding to boost access to world's first chikungunya vaccine
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
INOVIO names new chief commercial officer
Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial
Bavarian Nordic files for chikungunya vaccine approval in Europe
Valneva's chikungunya vaccine IXCHIQ approved by Health Canada
Philippine lawmakers call for probe into secret US propaganda operation
Gavi seeking funding to immunise poorest children
Sanofi partners with Biovac to manufacture polio vaccines in Africa